New Weight-Loss Pill Beats Oral Wegovy in Major Trial

ଅପରାଧ

ବ୍ରହ୍ମଗିରିରେ ପୂର୍ବ ଶତ୍ରୁତାକୁ ନେଇ ଯୁବକଙ୍କୁ ହତ୍ୟା ଅଭିଯୋଗ; କାଜୁ...

May 25, 2026

ବ୍ରହ୍ମପୁରରେ ଯୁବକଙ୍କୁ ଆକ୍ରମଣ: ଭାଇରାଲ ଭିଡିଓର ୫ ଘଣ୍ଟା ମଧ୍ୟରେ...

May 25, 2026

ବାଲିହନ୍ତା GRP କନଷ୍ଟେବଳ ମୃତ୍ୟୁ ମାମଲାରେ ୧୧ ଗିରଫ, ସାଙ୍ଗ...

May 09, 2026

ଭୁବନେଶ୍ୱରରେ ନିଶା କାରବାରକୁ କେନ୍ଦ୍ର କରି ଖଣ୍ଡା ଆକ୍ରମଣ, ୪...

May 09, 2026

ପାଣିପାଗ

ପଶ୍ଚିମ ଓଡ଼ିଶାରେ ୪୫ ଡିଗ୍ରୀ ଛୁଇଁଲା ତାପମାତ୍ରା; ସୁବର୍ଣ୍ଣପୁରରେ ଅସହ୍ୟ...

May 25, 2026

ଆହୁରି ବଢ଼ିବ ଓଡ଼ିଶାର ଗ୍ରୀଷ୍ମ ପ୍ରକୋପ; କେତେକ ଜିଲ୍ଲାକୁ ରେଡ୍‌...

May 25, 2026

ଆଗାମୀ ସପ୍ତାହରେ ଓଡ଼ିଶାରେ ଗରମ ସହ କାଳବୈଶାଖୀ ପ୍ରଭାବ, ତାପପ୍ରବାହ...

May 25, 2026

ମେ’ ୧୧ ପାଖାପାଖି ବଙ୍ଗୋପସାଗରରେ ନୂଆ ଲଘୁଚାପ ସମ୍ଭାବନା, ପାଣିପାଗ...

May 09, 2026

New Weight-Loss Pill Beats Oral Wegovy in Major Trial

A new oral weight-loss pill — orforglipron — has outperformed oral semaglutide (Wegovy) in a large head-to-head clinical trial, showing greater average weight loss and better blood sugar control. The results suggest a promising new treatment option as obesity drug developers race for approvals.

Published by Somesh | February 26, 2026

In a major development for obesity and metabolic health treatment,Eli Lilly’s experimental oral GLP-1 therapy, orforglipron, demonstrated superior results compared withoral semaglutide (Wegovy)in a largePhase 3 head-to-head trialinvolving nearly 1,700 participants with type 2 diabetes and overweight conditions. TheACHIEVE-3study, published inThe Lancet, showed that orforglipron — taken once daily — delivered significantly greater improvements inweight loss and blood sugar controlcompared with semaglutide at key measured doses, with results emerging as early as four weeks and sustained throughout the study period.

Participants receiving orforglipron experienced more substantial average weight reduction and larger drops inA1C(a key marker of blood glucose levels) than those on the semaglutide regimen, highlighting its potential dual benefit in metabolic and obesity management. Unlike semaglutide, which is often taken under fasted conditions, orforglipron does not require fasting before dosing, offering easier administration for patients. While exact regulatory timelines are pending, orforglipron’s performance positions it as a strong candidate to expand the oral GLP-1 therapeutic landscape if approved for obesity indications.

Experts note that this milestone underscores intense competition in the weight-loss drug market, where multiple companies are racing to develop effective, convenient, and accessible oral treatments. Patients seeking options beyond injectable therapies — such as weekly GLP-1 injections — may benefit from the emerging crop of oral agents, but the long-term safety profiles and regulatory decisions will be key to widespread adoption.